Subsequently, in the large randomised placebo-controlled FIDELIO-DKD trial including adults with type 2 diabetes and CKD, finerenone reduced the risk of the primary kidney outcome (a composite of kidney failure, sustained eGFR decline 40% or kidney death) by ~20% [69]
In an additional analysis using the KC mouse model, GLP-1 treatment was administered to animals with cerulein-induced pancreatitis
Action 3: Know the Difference Between Standard and Expedited Requesting expedited review when the clinical criteria are met reduces the decision window from 3 to 7 business days to 24 to 72 hours
Regional Insights North America GLP-1 Receptor Agonist Market Insights North America dominated the global GLP-1 Receptor Agonist Market in 2025 with approximately 45% of global revenues, anchored entirely by the United States' unique drug pricing environment and the commercial investment that Novo Nordisk and Eli Lilly have made in building GLP-1 prescribing across endocrinology, primary care, cardiology, and bariatric medicine
Expert guidance on nausea, vomiting, and illness
